Cargando…
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
Multiple targeted therapeutics have been approved by the FDA for mUC, including immune checkpoint inhibitors (ICIs) and more recently targeted agents for both FGFR and Nectin-4. FGFR3-aberrant and Nectin-4 expressing cells have been associated with an immunosuppressed phenotype. Given that less than...
Autores principales: | Nielsen, Tyler J., Varga, Matthew G., Cronister, Catherine T., Ring, Brian Z., Seitz, Robert S., Ross, Douglas T., Schweitzer, Brock L., McGregor, Kimberly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264529/ https://www.ncbi.nlm.nih.gov/pubmed/36806983 http://dx.doi.org/10.1007/s00262-023-03401-x |
Ejemplares similares
-
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
por: Seitz, Robert S., et al.
Publicado: (2022) -
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023) -
Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019) -
BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018) -
A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
por: Nielsen, Tyler J., et al.
Publicado: (2021)